Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
8 min read
DARS2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DARS2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DARS1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DARS1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DAOA Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DAOA, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DAD1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DAD1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DACT3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DACT3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DACT2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DACT2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
Latest Hotspot
8 min read
Fragile X syndrome Indication Strategy Report 2026: FMR1-AS1, Trials and Deals
21 July 2026
Fragile X syndrome indication strategy report covering epidemiology, FMR1-AS1 biology, active trials, competition and deal signals using PatSnap MCP evidence.
8 min read
DACT1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DACT1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DAAM2 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DAAM2, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
DAAM1 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for DAAM1, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYTH4 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYTH4, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.
8 min read
CYTH3 Target Evaluation Report 2026: Biology, Validation, Competition, IP, and R&D Strategy
21 July 2026
A visual target evaluation report for CYTH3, generated in a PatSnap Life Sciences MCP-style workflow covering biology, validation evidence, clinical competition, IP signals, and R&D strategy.